Drug development platform for non-immunosuppressive therapies that restore natural immune function in inflammatory diseases.
Promakhos Therapeutics is a Boston-based biotech developing medicines for chronic inflammatory diseases including Crohn's disease, Type 1 Diabetes, and Multiple Sclerosis. Unlike standard immunosuppressive treatments, their approach uses bacterial molecules to restore the body's innate ability to control inflammation and heal rather than suppressing the immune system. Their lead oral drug candidate for Crohn's disease has received a Phase 1 SBIR grant of $271,865 from NIDDK, and the company won the Harvard President's Innovation Challenge. Promakhos Therapeutics is a product of Promakhos Therapeutics.